IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin
New phase 3 data from the investigational therapy IDegLira were…
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...